Drugs / adenovirus-transfected autologous DC vaccine
adenovirus-transfected autologous DC vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02693236 | Aug 2014 → Aug 2016 | esophageal cancer | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adenovirus-transfected autologous DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02693236 ↗ |
| Modality | Cell therapy | “Experimental recombinant adenovirus coded mRNA including MUC1 and Survivin that transfected DC, which are used for DC-based immunotherapy.” NCT02693236 ↗ |